Goldman Sachs Group Inc Allakos Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Allakos Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 14,141 shares of ALLK stock, worth $16,969. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,141
Previous 343,668
95.89%
Holding current value
$16,969
Previous $343,000
97.38%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ALLK
# of Institutions
81Shares Held
64.7MCall Options Held
47.1KPut Options Held
1K-
Bvf Inc San Francisco, CA16.6MShares$19.9 Million0.34% of portfolio
-
Nea Management Company, LLC Timonium, MD6.15MShares$7.38 Million0.31% of portfolio
-
Deep Track Capital, LP Greenwich, CT5MShares$6 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.51MShares$4.22 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.08MShares$3.69 Million0.13% of portfolio
About Allakos Inc.
- Ticker ALLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 84,726,096
- Market Cap $102M
- Description
- Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...